MariTide
MariTide (Maridebart Cafraglutide)
The monthly incretin
An investigational once-monthly weight-loss drug from Amgen with an unusual design: it's a GLP-1 receptor agonist combined with a GIP receptor ANTAGONIST — the opposite of tirzepatide's GIP agonism. Built as an antibody-peptide conjugate, its real-world edge is convenience: monthly dosing instead of weekly, with sustained weight loss in Phase 2. Currently in the Phase 3 MARITIME programme; not approved.
Key Benefits
Once-monthly dosing — a real adherence and convenience edge
Sustained Phase 2 weight loss without an early plateau
Novel GLP-1 agonist / GIP antagonist mechanism
Antibody-conjugate design for extended half-life
Alternative for people who struggle with weekly injections
Mechanism of Action
How MariTide works
MariTide takes a contrarian approach to the incretin axis:
- GLP-1 receptor agonism — the familiar appetite-suppressing, satiety-promoting arm shared with every incretin drug
- GIP receptor antagonism — rather than activating GIP like tirzepatide, MariTide blocks it. Both agonizing and antagonizing GIP can aid weight loss through different downstream effects, and this is an active area of debate
- Antibody half-life — the molecule is conjugated to an antibody scaffold, extending its half-life enough to support genuine once-monthly dosing — a major adherence advantage
- Sustained loss — Phase 2 showed continued weight reduction without an early plateau, which is part of why monthly dosing is viable
Your Genetics & MariTide
Genetic variants that affect your response
These SNPs determine how effectively MariTide works for you specifically. A genetic peptide report identifies your variants before you start.
The Glu354Gln (E354Q) variant is a reduced-function, lower-BMI-associated allele. It's mechanistically congruent with a GIP-antagonist drug — but honesty matters here: no human pharmacogenetic study yet shows an E354Q carrier responds better to a GIP antagonist than to a GIP agonist. Treat it as a hypothesis, not a prediction.
A second reduced-function GIPR allele in the same direction. It adds to the mechanistic plausibility of the antagonist class, with the same caveat that direct response data don't yet exist.
FTO risk alleles raise appetite drive and set-point. As with all incretins, a higher genetic set-point is the case where a high-efficacy agent is most justified.
Shapes the GLP-1-agonist arm of MariTide. Weak-signaling variants can blunt the agonist component independent of the GIP-antagonist effect.
Which variants do you carry?
Upload your DNA data or order a kit to find out.
Evidence & Research
12+
Published studies
Animal studies and in vitro data with promising but limited clinical validation
Common Stacks
MariTide is commonly combined with:
Frequently Asked Questions
What is MariTide?
MariTide (maridebart cafraglutide) is an investigational once-monthly weight-loss drug from Amgen. It combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate, and its standout feature is monthly rather than weekly dosing.
Why does MariTide block GIP when tirzepatide activates it?
It's one of the genuine open questions in obesity pharmacology — both activating and blocking the GIP receptor appear to support weight loss through different mechanisms. MariTide bets on antagonism; tirzepatide on agonism. The Phase 3 data will help settle which wins for whom.
Is MariTide approved?
No. As of 2026 MariTide is investigational, in the Phase 3 MARITIME programme. It is not an available prescription.
Learn More About MariTide
Your next move
Two ways forward with MariTide.
Not sure it's for you?
Will MariTide work for your genes — and at what dose?
Your report scores MariTide against your receptor, CYP and pathway variants — likely responder, non-responder, and a sensible starting dose — in minutes.
Analyze my DNA — $99